Vascular Disrupting Agents Markets, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions” report has been added to ResearchAndMarkets.com’s offering.

The ‘Vascular Disrupting Agents Market, 2021-2030 report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade.

Presently, there are multiple small molecule VDAs, which have been / are being developed for the treatment of a variety of oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma and ovarian cancer. Moreover, combination therapies, involving VDAs and conventional chemotherapy, radiation therapy and radioimmunotherapy, have demonstrated excellent clinical responses in multiple animal models.

It is worth noting that the R&D efforts in this field are being supported by the National Institutes of Health, accounting for USD 95 million in research grants disbursed since 2016. Driven by encouraging clinical research, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030.

The report also features the likely distribution of the current and forecasted opportunity across

• Target indications (chemotherapy-induced neutropenia, glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, non-small cell lung cancer, prostate cancer, recurrent platinum resistant ovarian cancer, transitional cell cancer of renal pelvis and ureter)
• Therapeutic area (hematological malignancies, solid tumors and other therapeutic areas)
• Type of molecule (small molecule and ligand-directed agents)
• Type of therapy (monotherapy, combination therapy and both)
• Route of administration (oral, intravenous)
• Key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World).

Scope of the Report

Amongst other elements, the report includes:

• A detailed review of the current market landscape of vascular disrupting agents, including information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of product candidates, therapeutic area (hematological malignancies, solid tumors and others), target indication(s), type of molecule (small molecule (tubulin binding agents and flavonoids), and ligand directed agents), type of therapy (monotherapy, combination therapy and others) and route of administration (oral, intravenous and others). In addition, it presents a list of companies developing vascular disrupting agents and analysis based on year of establishment, company size and location of headquarters.
• Detailed profiles of the prominent players in this domain (shortlisted on the basis of number of vascular disrupting agents in development pipeline). Each profile features a brief overview of the company, its financial information (if available), detailed description (including information on the type of drug, current status of development, target indications, mode of action and type of therapy) of their respective lead drug candidates, recent developments and an informed future outlook.
• An in-depth analysis of completed, ongoing and planned clinical studies of various vascular disrupting agents, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus and key indications.
• A detailed review of more than 750 peer-reviewed, scientific articles related to research on vascular disrupting agents, which have been published during the period, 2016 – January 2021. The publications have been analyzed to highlight the trends across year of publication, emerging focus areas, popular keywords, key indications, key therapeutic areas, key research journals and popular authors.
• An in-depth analysis of grants awarded to various research institutes for the projects related to vascular disrupting agents, in the period between 2016 and January 2021, on the basis of parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.
• A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 22 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Key Questions Answered

• Who are the leading industry and non-industry players in this market?
• Which cancer indications can be treated with vascular disrupting agents?
• Which geographies are the most active in conducting clinical trials on vascular disrupting agents?
• What is the focus area of the research activities ongoing in this domain?
• Which are the leading administering institute centers supporting the research related to this domain?
• Who are the key opinion leaders that can help you drive your development efforts?
• How is the current and future market opportunity likely to be distributed across key market

For more information about this report visit https://www.researchandmarkets.com/r/cslqqk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900